

# Molecular Therapeutics of Cancer Research Conference -- 2015

Sponsored by the Cancer Molecular Therapeutics Research Association

## TUFTS UNIVERSITY, Medford, Massachusetts

### Schedule and Program

*IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.*

**All scientific sessions will be in the Cohen Auditorium, Building 17**

**Breaks, Poster sessions with refreshments will be in the Alumni Lounge, Building 4**

**The opening reception Sunday evening will be in the Lemis Sculpture Court, Building 1**

**The farewell reception will be on the Tisch Library Roof Garden, Building 59 [Rain location, Lemis Sculpture Court]**

**Lodging will be in South Hall, Building 55**

**Meals will be in Dewick-MacPhie Dinning Hall, Building 23. Please use the upper level seating area.**

#### **SUNDAY – JULY 12**

4:00 pm	Arrival and check-in at South Hall, Building 55
6:00 – 7:00 pm	<i>Dinner Dewick-MacPhie Dinning Hall</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX, President CMTRA Mary-Ann Bjornsti, University of Alabama, Birmingham, AL, Program Coordinator
7:45 – 10:00 pm	<b>EVENING SESSION: “Targeted Protein Degradation”</b>  Discussion Leader: Jim Winkler, Arvinas, New Haven, CT
7:45 – 8:00 pm	Introduction
8:00 – 8.30 pm	Craig Crews, Yale University, New Haven, CT "Targeted Protein Degradation – What it Provides and How to Achieve It"
8:30 – 8:55 pm	Discussion
9:00 – 9:30 pm	Mark Rolfe, Cleave Biosciences, Burlingame, CA “New Ways of Targeting Protein Homeostasis: Novel p97 Inhibitors for the Treatment of Cancer”
9:35 – 10:00 pm	Discussion
10:00 pm –	<i>Opening reception Lemis Sculpture Court</i>

**MONDAY – JULY 13**

7:30 – 8:15 am	<i>Breakfast Dewick-MacPhie Dinning Hall</i>
8:30 – 12:00 pm	<b>MORNING SESSION: – “BCL2 and MCL1 Inhibitors – Opening the Door to Protein-Protein Interaction Inhibitors”</b>  Discussion Leader: Alan Eastman, Geisel School of Medicine at Dartmouth, Hanover, NH
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Joel Levenson, AbbVie, North Chicago, IL “Clinical Proof of Concept for the First-in-Class BCL-2-Selective Inhibitor Venetoclax (ABT-199/ GDC-0199)”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break Alumni Lounge</i>
10:00 – 10:30 am	Olivier Geneste, Servier, Paris, FR “Development of Selective Inhibitors of MCL1”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Jeff Engleman, Massachusetts General Hospital Cancer Center, Boston, MA “Translating Apoptosis Modulation into Clinical Efficacy”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch Dewick-MacPhie Dinning Hall</i>
2:00 – 4:10 pm	<b>AFTERNOON SESSION: “Circulating Biomarkers, CTCs and ctDNA”</b>  Discussion Leader: Caroline Dive, Cancer Research UK, Manchester, UK
2:00 – 2:15 pm	Introduction
2:15 – 2:45 pm	Alain Thierry, Montpellier Cancer Research Institute, Montpellier, FR “Circulating Cell-Free DNA as a Strong Multimarker Diagnostic, Theranostic and Prognostic Tool”
2:45 – 3:10 pm	Discussion
3:15 – 3:45 pm	Victor Velculescu, Johns Hopkins University “Title”
3:45 – 4:10 pm	Discussion
4:30 – 6:00 pm	<b>Poster Session and Social</b> <i>Alumni Lounge</i>
6:00 – 7:00 pm	<i>Dinner Dewick-MacPhie Dinning Hall</i>

7:30 – 9:45 pm **EVENING SESSION: “A Call to Arms: How Can We Improve Cancer Drug Development?”**  
 Discussion Leaders: Dan Hoth, San Francisco, CA, and Brandy Sikic, Stanford, CA

7:30 – 7:45 pm Introduction – Brandy Sikic

7:45 – 8:45 pm Short Presentations:  
 Susan Galbraith, AstraZeneca, Manchester, UK: “Astrazeneca’s pipeline success analysis”  
 Vicky Richon, Sanofi, Cambridge, MA: “Discovery and validation of new targets”  
 Pam Carroll, J&J Oncology Innovation Center, Boston: “Industry-Academic collaboration”  
 Ian Tannock, University of Toronto, Toronto: “Are we setting the bar too low in Phase III?”

8:45 – 9:45 pm Group Discussion  
 Above presenters, plus:  
 Rob Kramer, Consultant, Princeton, NJ  
 Christoph Lengauer, Blueprint Medicines, Cambridge, MA  
 Greg Plowman, Lilly Oncology Discovery, Indianapolis, IN

9:45 pm – *Social - Alumni Lounge*

**TUESDAY JULY 14**

7:30 – 8:15 am *Breakfast Dewick-MacPhie Dinning Hall*

8:30 – 12:00 pm **MORNING SESSION: “Is Flat Biology Dead”**  
 Discussion Leader: John Hickman

8:30 – 8:45 am Introduction

8:45 – 9:15 am Christopher Chen, Boston University, Boston, MA  
 “Engineering Microenvironments to Study Tissue Remodeling in Vitro”

9:15 – 9:40 am Discussion

9:40 – 10:00 am *Coffee Break Alumni Lounge*

10:00 – 10:30 am Bonnie Sloane, Wayne State University School of Medicine, Detroit, MI  
 “The Cutting Edge of Cancer: Now Playing in Living Color and 4D”

10:30 – 10:55 am Discussion

11:00 – 11:30 am Donald Ingber, Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA  
 “Human Organs-on-Chips”

11:30 – 11:55 am Discussion

12:00 – 1:00 pm *Lunch Dewick-MacPhie Dinning Hall*

1:00 – 4:30 pm **OPEN NETWORKING AFTERNOON**

4:30 – 5:45 pm **Poster Session and Social** *Alumni Lounge*

6:00 – 7:00 pm	<i>Dinner Dewick-MacPhie Dinning Hall</i>
7:30 – 9:45 pm	<b>EVENING SESSION: “Preclinical models for immunotherapies”</b>
	Discussion Leader: Robert Kramer
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	Kwok Kim-Wong, Dana Farber Cancer Institute, Boston, MA “Tumor immunology in genetically engineered mouse models of lung cancer”
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	TBA
9:15 – 9:40 pm	Discussion
9:45 pm –	<i>Social Alumni Lounge</i>

### WEDNESDAY JULY 15

7:30 – 8:15 am	<i>Breakfast Dewick-MacPhie Dinning Hall</i>
8:30 – 11:00 am	<b>MORNING SESSION: “Cell Cycle and CDK Resurrection”</b>
	Discussion Leader: Phil Denis,
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Geoff Shapiro, Dana-Farber Cancer Institute, Boston, MA "CDK4/6 Inhibition and Cancer Therapy"
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break Alumni Lounge</i>
10:00 – 10:30 am	Susan Galbraith, AstraZeneca “Development and clinical application of a Wee1 inhibitor”
10:30 – 10:55 am	Discussion
11:00 – 12:00 pm	<b>ORAL PRESENTATIONS – Four Selected Presenters from the Posters</b>
12:00 – 1:00pm	<i>Lunch Dewick-MacPhie Dinning Hall</i>
2:00 – 5:20 pm	<b>AFTERNOON SESSION: “Colorectal Cancer”</b>
	Discussion Leader: Sandy Markowitz, Case Western Reserve, Cleveland, OH
2:00 – 2:15 pm	Introduction

2:15 – 2:45 pm	Scott Waldman, Thomas Jefferson University Hospital, Philadelphia, PA “The Paracrine Hormone Hypothesis of Colorectal Cancer”
2:45 – 3:10 pm	Discussion
3:10 – 3:40 pm	Dan Liebler, Vanderbilt Ingram Cancer Center, Nashville, TN “Proteogenomic Characterization of Human Colon and Rectal Cancer”
3:40 – 4:05 pm	Discussion
4:05 – 4:25 pm	<i>Coffee Break Alumni Lounge</i>
4:25 – 4:55 pm	Sandy Markowitz, Case Western Reserve, Cleveland, OH “15-PGDH Targeted Therapy in Cancer and Other Diseases”
4:55 – 5:20 pm	Discussion
6:00 – 10:00 pm	<b><i>Farewell Reception Tisch Library Roof Garden</i></b>

#### THURSDAY JULY 16

7:00 - 8:30 am *Breakfast Dewick-MacPhie Dinning Hall*

CHECK OUT BY 11:00 AM

#### SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

Genentech  
Jansen Research and Development  
Pfizer

#### MOLECULAR THERAPEUTICS OF CANCER RESEARCH CONFERENCE 2016 – SAVE THE DATE!!

**Location**

**PROGRAM CHAIR: TBD  
JULY 10-14, 2016**